Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Advancing Phage Therapy through Synergistic Strategies: Phage-Mediated Killing and Competitive Exclusion using Engineered Prophages

Project description

New technology for improved phage therapy

With the rise of antibiotic resistance, phage therapy is a promising alternative treatment. However, its widespread adoption has been hindered by challenges such as the lengthy process of identifying suitable phages and their limited effectiveness in living organisms. The ERC-funded PHAGE-PRO project aims to address these challenges by leveraging a novel approach that combines engineered prophages (viruses that integrate into bacterial genomes) with probiotic strains. This allows for the rapid identification of effective phages through machine learning. The project’s focus is on developing tools to identify optimal combinations of prophages and probiotics, as well as conducting high-throughput experiments to validate their efficacy. The results could also pave the way for applications in human medicine.

Objective

Amid the antibiotic resistance crisis, the century-old practice of phage therapy, the use of bacterial viruses to treat bacterial infections, has gained renewed attention. Despite extensive research and clear-cut advantages over antibiotics, phage therapy has yet to gain momentum. This is primarily due to remaining limitations, e.g. the time-consuming process of identifying suitable phages and limited in vivo efficacy.
With PHAGE-PRO I propose a new technology to overcome the shortcomings of traditional phage therapy. Unlike the conventional use of lytic phages, I will capitalize on prophages – viruses that integrate into bacterial genomes capable of excision and replication. By integrating prophages into safe carrier strains, originating from probiotics, I will unlock two pivotal benefits, (1) rapid identification of suitable phages using advanced machine learning, (2) sustained in-vivo efficacy. Yet, the core advantage of PHAGE-PRO lies in its unparalleled synergy of phage killing and pathogen competitive exclusion imposed by the probiotic.
To realize this concept, the development of predictive tools is essential to quickly identify the most promising prophages and probiotic combinations for each pathogen (WP1). Prophage engineering (WP2), followed by rigorous in vitro testing will ensure a high safety and efficacy. High-throughput in vivo experiments using wax moth larvae will reveal the most promising candidate which I will subsequently validate through a proof of principle experiment using a poultry model (WP3).
Although I initially tailored PHAGE-PRO to treat Salmonella infections in poultry, its impact extends far beyond: This new technology holds the potential for transformative changes in phage therapy, not only advancing infection management in livestock farming through the enhancement of animal health and the assurance of food product safety, but also by opening the door for targeted preventive and therapeutic interventions in human medicine.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2024-STG

See all projects funded under this call

Host institution

LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Net EU contribution
€ 1 071 087,00
Address
GESCHWISTER SCHOLL PLATZ 1
80539 Planegg
Germany
Region
Bayern Oberbayern München, Kreisfreie Stadt
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 1 071 087,00

Beneficiaries (2)